Literature DB >> 27614919

Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.

Samantha M Gromek1, James A deMayo1, Andrew T Maxwell1, Ashley M West1, Christopher M Pavlik1, Ziyan Zhao2, Jin Li1, Andrew J Wiemer1, Adam Zweifach2, Marcy J Balunas3.   

Abstract

Santacruzamate A (SCA) is a natural product isolated from a Panamanian marine cyanobacterium, previously reported to have potent and selective histone deacetylase (HDAC) activity. To optimize the enzymatic and cellular activity, 40 SCA analogues were synthesized in a systematic exploration of the zinc-binding group (ZBG), cap terminus, and linker region. Two cap group analogues inhibited proliferation of MCF-7 breast cancer cells, with analogous increased degranulation of cytotoxic T cells (CTLs), while one cap group analogue reduced CTL degranulation, indicative of suppression of the immune response. Additional testing of these analogues resulted in reevaluation of the previously reported SCA mechanism of action. These analogues and the resulting structure-activity relationships will be of interest for future studies on cell proliferation and immune modulation.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-proliferative activity; Enzyme assays; Immune modulation; Natural product analogues; Santacruzamate A

Mesh:

Substances:

Year:  2016        PMID: 27614919      PMCID: PMC5065774          DOI: 10.1016/j.bmc.2016.08.040

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  35 in total

1.  Symplostatin 3, a new dolastatin 10 analogue from the marine cyanobacterium Symploca sp. VP452.

Authors:  Hendrik Luesch; Wesley Y Yoshida; Richard E Moore; Valerie J Paul; Susan L Mooberry; Thomas H Corbett
Journal:  J Nat Prod       Date:  2002-01       Impact factor: 4.050

Review 2.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Authors:  Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

3.  A new generation of specific Trypanosoma cruzi trans-sialidase inhibitors.

Authors:  Sabrina Buchini; Alejandro Buschiazzo; Stephen G Withers
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

Review 4.  New patented histone deacetylase inhibitors.

Authors:  Haishan Wang; Brian W Dymock
Journal:  Expert Opin Ther Pat       Date:  2009-12       Impact factor: 6.674

5.  Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1.

Authors:  H Luesch; R E Moore; V J Paul; S L Mooberry; T H Corbett
Journal:  J Nat Prod       Date:  2001-07       Impact factor: 4.050

6.  Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.

Authors:  Marcus Bantscheff; Carsten Hopf; Mikhail M Savitski; Antje Dittmann; Paola Grandi; Anne-Marie Michon; Judith Schlegl; Yann Abraham; Isabelle Becher; Giovanna Bergamini; Markus Boesche; Manja Delling; Birgit Dümpelfeld; Dirk Eberhard; Carola Huthmacher; Toby Mathieson; Daniel Poeckel; Valérie Reader; Katja Strunk; Gavain Sweetman; Ulrich Kruse; Gitte Neubauer; Nigel G Ramsden; Gerard Drewes
Journal:  Nat Biotechnol       Date:  2011-01-23       Impact factor: 54.908

7.  Total synthesis and molecular target of largazole, a histone deacetylase inhibitor.

Authors:  Yongcheng Ying; Kanchan Taori; Hyoungsu Kim; Jiyong Hong; Hendrik Luesch
Journal:  J Am Chem Soc       Date:  2008-05-29       Impact factor: 15.419

8.  Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.

Authors:  Christopher M Pavlik; Christina Y B Wong; Sophia Ononye; Dioxelis D Lopez; Niclas Engene; Kerry L McPhail; William H Gerwick; Marcy J Balunas
Journal:  J Nat Prod       Date:  2013-10-28       Impact factor: 4.050

9.  Identification of preferential target sites for human DNA methyltransferases.

Authors:  Si Ho Choi; Kyu Heo; Hyang-Min Byun; Woojin An; Wange Lu; Allen S Yang
Journal:  Nucleic Acids Res       Date:  2010-09-13       Impact factor: 16.971

10.  Combining mass spectrometry and peptide arrays to profile the specificities of histone deacetylases.

Authors:  Zachary A Gurard-Levin; Joohoon Kim; Milan Mrksich
Journal:  Chembiochem       Date:  2009-09-04       Impact factor: 3.164

View more
  5 in total

1.  CAY10683 and imatinib have synergistic effects in overcoming imatinib resistance via HDAC2 inhibition in chronic myeloid leukemia.

Authors:  Tianzhuo Zhang; Danna Wei; Tingting Lu; Dan Ma; Kunlin Yu; Qin Fang; Zhaoyuan Zhang; Weili Wang; Jishi Wang
Journal:  RSC Adv       Date:  2020-01-03       Impact factor: 4.036

Review 2.  Marine Cyanobacteria as Sources of Lead Anticancer Compounds: A Review of Families of Metabolites with Cytotoxic, Antiproliferative, and Antineoplastic Effects.

Authors:  Benjamín Robles-Bañuelos; Lorena María Durán-Riveroll; Edgar Rangel-López; Hugo Isidro Pérez-López; Leticia González-Maya
Journal:  Molecules       Date:  2022-07-27       Impact factor: 4.927

Review 3.  Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer.

Authors:  Siddhartha Das Pramanik; Amit Kumar Halder; Ushmita Mukherjee; Dharmendra Kumar; Yadu Nandan Dey; Mogana R
Journal:  Front Chem       Date:  2022-08-12       Impact factor: 5.545

4.  The Protective Mechanism of CAY10683 on Intestinal Mucosal Barrier in Acute Liver Failure through LPS/TLR4/MyD88 Pathway.

Authors:  Yao Wang; Hui Chen; Qian Chen; Fang-Zhou Jiao; Wen-Bin Zhang; Zuo-Jiong Gong
Journal:  Mediators Inflamm       Date:  2018-03-13       Impact factor: 4.711

Review 5.  Marine Cyanobacteria: A Source of Lead Compounds and their Clinically-Relevant Molecular Targets.

Authors:  Lik Tong Tan; Ma Yadanar Phyo
Journal:  Molecules       Date:  2020-05-08       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.